Premedication with oral alprazolam and melatonin combination: a comparison with either alone--a randomized controlled factorial trial

Krishna Pokharel, Mukesh Tripathi, Pramod Kumar Gupta, Balkrishna Bhattarai, Sindhu Khatiwada, Asish Subedi, Krishna Pokharel, Mukesh Tripathi, Pramod Kumar Gupta, Balkrishna Bhattarai, Sindhu Khatiwada, Asish Subedi

Abstract

We assessed if the addition of melatonin to alprazolam has superior premedication effects compared to either drug alone. A prospective, double blind placebo controlled trial randomly assigned 80 adult patients (ASA 1&2) with a Visual Analogue Score (VAS) for anxiety ≥ 3 to receive a tablet containing a combination of alprazolam 0.5 mg and melatonin 3 mg, alprazolam 0.5 mg, melatonin 3 mg, or placebo orally 90 min before a standard anesthetic. Primary end points were change in anxiety and sedation score at 15, 30, and 60 min after premedication, and number of patients with loss of memory for the five pictures shown at various time points when assessed after 24 h. One-way ANOVA, Friedman repeated measures analysis of variance, Kruskal Wallis and chi square tests were used as relevant. Combination drug produced the maximum reduction in anxiety VAS (3 (1.0-4.3)) from baseline at 60 min (P < 0.05). Sedation scores at various time points and number of patients not recognizing the picture shown at 60 min after premedication were comparable between combination drug and alprazolam alone. Addition of melatonin to alprazolam had superior anxiolysis compared with either drugs alone or placebo. Adding melatonin neither worsened sedation score nor the amnesic effect of alprazolam alone. This study was registered, approved, and released from ClinicalTrials.gov. Identifier number: NCT01486615.

Figures

Figure 1
Figure 1
A flow diagram showing inclusion, exclusion, group allocation, intervention and follow up.
Figure 2
Figure 2
Change in anxiety VAS (median (IR)) relative to baseline after premedication. ∙ = outlier, ∗ = extreme value.

References

    1. Moyers JR, Vincent CM. Preoperative medication. In: Barash PG, Cullen BF, Stoelting RK, editors. Clinical Anesthesia. 4th edition. Philadelphia, Pa, USA: Lippincott-Raven; 1997. pp. 551–563.
    1. Dawson D, Encel N. Melatonin and sleep in humans. Journal of Pineal Research. 1993;15(1):1–12.
    1. Ansseau M, Doumont A, Diricq S. Methodology required to show clinical differences between benzodiazepines. Current Medical Research and Opinion. 1984;8(4):108–114.
    1. Naguib M, Samarkandi AH. Premedication with melatonin: a double-blind, placebo-controlled comparison with midazolam. British Journal of Anaesthesia. 1999;82(6):875–880.
    1. Naguib M, Samarkandi AH. The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: a double-blinded, placebo-controlled study. Anesthesia and Analgesia. 2000;91(2):473–479.
    1. Yousaf F, Seet E, Venkatraghavan L, Abrishami A, Chung F. Efficacy and safety of melatonin as an anxiolytic and analgesic in the perioperative period: a qualitative systematic review of randomized trials. Anesthesiology. 2010;113(4):968–976.
    1. Aitken RC. Measurement of feelings using visual analogue scales. Proceedings of the Royal Society of Medicine. 1969;62(10):989–993.
    1. De Witte JL, Alegret C, Sessler DI, Cammu G. Preoperative alprazolam reduces anxiety in ambulatory surgery patients: a comparison with oral midazolam. Anesthesia and Analgesia. 2002;95(6):1601–1606.
    1. Brzezinski A. Melatonin in humans. The New England Journal of Medicine. 1997;336(3):186–195.
    1. Naguib M, Gottumukkala V, Goldstein PA. Melatonin and anesthesia: a clinical perspective. Journal of Pineal Research. 2007;42(1):12–21.
    1. Capuzzo M, Zanardi B, Schiffino E, et al. Melatonin does not reduce anxiety more than placebo in the elderly undergoing surgery. Anesthesia and Analgesia. 2006;103(1):121–123.
    1. Ionescu D, Bãdescu C, Itie C, et al. Melatonin as premedication for laparoscopic cholecystectomy: a double-blind, placebo-controlled study. Southern African Journal of Anaesthesia and Analgesia. 2008;14(4):8–11.
    1. Verster JC, Volkerts ER. Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. CNS Drug Reviews. 2004;10(1):45–76.
    1. Borbely AA, Mattmann P, Loepfe M. Effect of benzodiazepine hypnotics on all-night sleep EEG spectra. Human Neurobiology. 1985;4(3):189–194.
    1. Wurtman RJ, Zhdanova I. Improvement of sleep quality by melatonin. The Lancet. 1995;346(8988):p. 1491.
    1. De Seabra MLV, Bignotto M, Pinto LR, Jr., Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. Journal of Pineal Research. 2000;29(4):193–200.
    1. Dawson GW, Jue SG, Brogden RN. Alprazolam. A review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression. Drugs. 1984;27(2):132–147.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel